This trial is evaluating whether Orelabrutinib (ICP-022) will improve 2 primary outcomes and 5 secondary outcomes in patients with Cancer. Measurement will happen over the course of Incidence of dose limiting toxicities (DLTs) up to 28 days.
This trial requires 81 total participants across 2 different treatment groups
This trial involves 2 different treatments. Orelabrutinib (ICP-022) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Although the exact reasons for cancer remain unknown, several factors are known to contribute to its development. In contrast, cancer is treated successfully by various modalities." - Anonymous Online Contributor
"The American Cancer Society estimates 274,000 new diagnoses of cancer will be made in 2018 in the United States alone. This makes up 22% of all new cancer diagnoses in America. It is estimated there will be 24,000 fewer cancer-related deaths in 2018 compared to 2014. A significant part of these new patients will die from breast and colorectal cancer due to advances in the early-detection of these cancers.\n" - Anonymous Online Contributor
"It can be curable, but the question remains as to how. Some people can be cured but in all cases an ongoing challenge is to cure cancers that do recur. Clearly, the best time for this is during the early stage before there is any spread of disease." - Anonymous Online Contributor
"The most common signs of cancer include persistent cough, shortness of breath and a lump. An abdominal mass may be palpable, and this may signify a gastrointestinal cancer. \n" - Anonymous Online Contributor
"It is not clear why cancer seems to prefer women, why cancer seems to be genetically inherited, or why men are at a much higher risk of developing cancer after the age of 60. Recent findings point to viruses as a common cause of cancer, particularly cervical cancer and possibly some kinds of cancers of the breast and prostate. \n\n- Cancer in India\n- List of cancers in India\n- List of cancers\n\n1. Pachamalinga Rao, M B, ed. Clinical Oncology, vol." - Anonymous Online Contributor
"A number of cancer treatments are used to treat cancer, including a variety of therapies like chemotherapy and medical radiotherapy, and the use of innovative medical treatments. Many cancer treatments are provided free of charge by patients themselves. A variety of cancer treatments exist which are available to patients depending on the type of cancer being treated. For instance, the most common treatment for cancer is chemotherapy. There are treatments for cancer patients of all ages including childhood cancer, children's cancer, adult cancer, and cancer in older adults." - Anonymous Online Contributor
"Given the poor clinical results and the toxicity profile for IPC-022 across multiple studies and indications, we would argue against further development of this agent in this indication." - Anonymous Online Contributor
"Considering the prevalence of cancer in the family, it is unlikely, but not impossible, for families to have two or more first-degree relatives who have been diagnosed with cancer." - Anonymous Online Contributor
"A Phase I study of orelabrutinib in elderly subjects demonstrated manageable side effects and provided a framework for evaluating phase II safety, activity, and clinical relevance for patients ≥60 years of age." - Anonymous Online Contributor
"The majority of patients undergoing surgery experienced improvement in cancer related symptoms, but there were also few patients with no improvement in symptoms. A small percentage of patients showed a worsening of symptoms. There was no significant difference in the symptoms that improved for patients with different types of tumors. Patients with large bowel cancer had fewer improvements in symptoms compared with those with other types of tumors. Patients with the advanced type of lung cancer had fewer improvements in symptom related to lung cancer. There was no difference in the amount of patients who gained weight from chemotherapy and those who lost weight from chemotherapy. Patients who received chemotherapy, had fewer improvements in symptoms, had worse symptoms on the day of chemotherapy, and had more nausea and vomiting after chemotherapy had more adverse events at any time interval." - Anonymous Online Contributor
"Combined with ixabepilone, orelabrutinib has significant activity in preclinical models of advanced solid tumors, both in the presence and absence of other mutations, and, while clinically evaluated in a phase II trial in patients with advanced gastrointestinal malignancies, was generally well tolerated and did not appear to compromise response rates to other targeted agents." - Anonymous Online Contributor
"Recent findings should help providers to better understand their patients' needs when it comes to making decisions regarding clinical trials, especially for treatment-intense cancers such as metastatic cancer and leukemia. Recent findings suggested that patients with a history of cancer should be considered when discussing clinical trials. They may need individualized information and may be in a position to evaluate the risk vs benefit. Moreover, patients with cancer should be addressed in regard to the type and dosage of cancer therapy available to them, as well as their likelihood for obtaining and responding to medical therapy." - Anonymous Online Contributor